Myrio Tx
Matthew Beasley is a seasoned biochemist and molecular biologist with extensive experience in leadership roles within the biotechnology sector. As Co-Founder of Hula Therapeutics since May 2021, and Chief Scientific Officer at Myrio Tx since January 2010, Matthew has demonstrated a strong commitment to advancing therapeutic innovations. Previously, Matthew served as Chief Scientific Officer at Alchemy Biosciences from September 2006 to January 2010. Matthew holds a Bachelor of Science (Hons) degree in Biochemistry and Molecular Biology from the University of Melbourne, earned between 1993 and 1996.
This person is not in any teams
Myrio Tx
Cancer will have no place to hide... Myrio Therapeutics ("Myrio Tx") is about to revolutionize the field of immuno-oncology by enabling antibody-based therapies to attack targets that are inside cells such as mutated cancer-causing and viral proteins. Proteins inside cells are routinely broken down into peptides which are displayed on the cell surface by Major Histocompatibility Complex (MHC), the targets of T-Cells. Myrio Tx’s protein-display system can discover antibodies against difficult to hit targets such as peptide-MHC complexes. This ability increases the number of addressable cancer or viral targets by a factor of ten. Based on fully-human sequences, discovered antibodies can be formatted to fit any purpose, from targeting CAR-T cells, antibody-drug conjugates, bispecifics or traditional antibodies. Myrio Tx's discovery platform can generate high affinity (low nM/pM) and highly selective scFv (antibody fragments) in a matter of days, allowing for rapid evaluation and optimization of product candidates. Myrio Tx is seeking partnerships to fully exploit the potential of its technology whilst also building an in-house portfolio of products.